HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan

This article was originally published in The Rose Sheet

Executive Summary

FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.

You may also be interested in...



Trade Group Urges FDA To Look Beyond Scale In Regulating Nanotechnology

FDA should not use size alone to regulate nanotechnology, the Consumer Healthcare Products Association says.

FDA Committed To Advancing Its Regulatory Science Capacity

FDA cites "advances in the application of nanotechnology" among scientific "breakthroughs" that are revolutionizing the health-care community's ability to treat disease, making the notion of personalized care a reality and demanding more FDA involvement

Owner Of Sunscreen Testing Lab AMA Awaits Sentencing Following Guilty Plea In US Federal Case

Gabriel Letizia Jr. potentially faces up to seven years in prison after admitting to defrauding AMA Laboratories customers of more than $46m by sending them bogus testing reports. The US FDA, which participated in the investigation, has not commented publicly on the implications for improperly tested sunscreens and other products.

UsernamePublicRestriction

Register

RS017746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel